Clinical Trial Update: Danicopan PMS in Korea

View source ↗

Summary

AstraZeneca’s Danicopan is enrolling in a post-marketing surveillance study in Korea for Paroxysmal Nocturnal Hemoglobinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: AstraZeneca | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Status: RECRUITING